Boston Scientific EVP reports 401(k) share rebalancing

Boston Scientific executive Arthur C. Butcher reported a discretionary rebalancing transaction in the company’s 401(k) plan involving 6,851 shares of common stock at $75.76 per share.

Rhea-AI Filing Summary

Boston Scientific executive Arthur C. Butcher reported a discretionary rebalancing transaction in the company’s 401(k) plan involving 6,851 shares of common stock at $75.76 per share. This was an indirect transaction under the company’s 401(k) Retirement Savings Plan, treated as a discretionary transaction under Rule 16b-3(f).

Following this plan-related activity, his indirect 401(k) holdings were 20,205 shares of Boston Scientific common stock, and his directly held position was 55,792 shares. The filing reflects a retirement-plan allocation decision rather than a traditional open-market purchase or sale.

Insider Trade Summary

Discretionary: 6,851 shares

Discretionary 2 txns

Insider Butcher Arthur C

Role EVP& Grp Pres, MedSurg & APAC

Type	Security	Shares	Price	Value
Discretionary	Common Stock	6,851	$75.76	$519K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 20,205 shares (Indirect, By 401(k)); Common Stock — 55,792 shares (Direct)

Footnotes (2)

1. F1. Acquistion made pursuant to an election by the reporting person to rebalance their holdings under the Company's 401(k) Retirement Savings Plan, which resulted in a discretionary transaction in shares of the Company's common stock.
2. F2. Balance reflects the most current data available with regard to share holdings in the Company's 401(k) Retirement Savings Plan.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Boston Scientific (BSX) EVP Arthur Butcher report in this Form 4?

Arthur C. Butcher reported a discretionary rebalancing transaction in Boston Scientific common stock within the company’s 401(k) Retirement Savings Plan, involving 6,851 shares at $75.76 per share, classified under Rule 16b-3(f) as a plan-related allocation rather than a typical market trade.

Was the Boston Scientific (BSX) Form 4 for Arthur Butcher a stock purchase or sale?

The Form 4 describes a discretionary 401(k) plan rebalancing, not a standard open-market stock purchase or sale. It involved reallocating 6,851 shares of Boston Scientific common stock within the company’s retirement plan under Rule 16b-3(f), reflecting an internal plan transaction.

How many Boston Scientific (BSX) shares does Arthur Butcher hold after the reported transaction?

After the reported activity, Arthur C. Butcher indirectly held 20,205 Boston Scientific common shares through the company’s 401(k) plan and directly held 55,792 common shares. These figures reflect the most current retirement-plan balance and his separate direct ownership position reported in the filing.

What is the nature of Arthur Butcher’s indirect Boston Scientific (BSX) ownership?

Arthur C. Butcher’s indirect ownership is through Boston Scientific’s 401(k) Retirement Savings Plan. The Form 4 notes 20,205 shares held via this plan after the discretionary rebalancing transaction, with the balance reflecting the most current data available on his retirement-plan share holdings.

What does a discretionary transaction under Rule 16b-3(f) mean for Boston Scientific (BSX)?

A discretionary transaction under Rule 16b-3(f) typically involves an insider’s election to change investment allocations in an issuer’s benefit or retirement plan. For Boston Scientific, Arthur Butcher’s 6,851-share 401(k) rebalancing is treated as such a plan-based allocation decision, not a conventional market trade.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/27/2026 - 05:31 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Butcher Arthur C

(Last) (First) (Middle)

300 BOSTON SCIENTIFIC WAY

(Street)

MARLBOROUGH MA 01752-1234

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BOSTON SCIENTIFIC CORP [ BSX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP& Grp Pres, MedSurg & APAC

3. Date of Earliest Transaction (Month/Day/Year)
02/19/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/19/2026		I(1)		6,851	A	$75.76	20,205(2)	I	By 401(k)
Common Stock								55,792	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Acquistion made pursuant to an election by the reporting person to rebalance their holdings under the Company's 401(k) Retirement Savings Plan, which resulted in a discretionary transaction in shares of the Company's common stock.

2. Balance reflects the most current data available with regard to share holdings in the Company's 401(k) Retirement Savings Plan.

	/s/ Susan Thompson, Attorney-in-Fact	02/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.